Citation: | CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong. Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(7): 727-732. DOI: 10.3971/j.issn.1000-8578.2022.21.1241 |
The majority of diagnosed cases of gastric cancer are in the middle and late stages, while less than 10% of patients are diagnosed in the early stages in China. The standard treatment strategy for patients with progressive gastric cancer is surgery combined with postoperative adjuvant therapy or preoperative neoadjuvant followed by surgery combined with postoperative adjuvant therapy. Immunotherapy is now recognized as an innovative approach for cancers. It is worth exploring how to best use immunotherapy in neoadjuvant therapy to achieve better clinical benefit. Therefore, this paper reviews the progress of immunotherapy in neoadjuvant therapy for GC. Further studies and the understanding of immune system function by neoadjuvant therapy combined with immunotherapy will help to improve the treatment of gastric cancer.
Competing interests: The authors declare that they have no competing interests.
[1] |
Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview[J]. Int J Cancer, 2021. [Online ahead of print]
|
[2] |
Shitara K, Honma Y, Omuro Y, et al. Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study[J]. Asia Pac J Clin Oncol, 2020, 16(1): 5-13. doi: 10.1111/ajco.13243
|
[3] |
Li K, Tian H. Development of small-molecule immune checkpoint inhibitors of PD-1/PD-L1 as a new therapeutic strategy for tumour immunotherapy[J]. J Drug Target, 2019, 27(3): 244-256. doi: 10.1080/1061186X.2018.1440400
|
[4] |
Zimmer L, Livingstone E, Hassel JC, et al. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage Ⅳ melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2020, 395(10236): 1558-1568. doi: 10.1016/S0140-6736(20)30417-7
|
[5] |
Fuchs CS, DoiT, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial[J]. JAMA Oncol, 2018, 4(5): e180013. doi: 10.1001/jamaoncol.2018.0013
|
[6] |
Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial[J]. Lancet Oncol, 2016, 17(6): 717-726. doi: 10.1016/S1470-2045(16)00175-3
|
[7] |
Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 390(10111): 2461-2471. doi: 10.1016/S0140-6736(17)31827-5
|
[8] |
Kawazoe A, Shitara K, Boku N, et al. Current status of immunotherapy for advanced gastric cancer[J]. Jpn J Clin Oncol, 2021, 51(1): 20-27. doi: 10.1093/jjco/hyaa202
|
[9] |
Ai L, Xu A, Xu J. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond[J]. Adv Exp Med Biol, 2020, 1248: 33-59.
|
[10] |
Shitara K, Özgüroğlu M, Bang YJ, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial[J]. Lancet, 2018, 392(10142): 123-133. doi: 10.1016/S0140-6736(18)31257-1
|
[11] |
Shitara K, Van Cutsem E, Bang YJ, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial[J]. JAMA Oncol, 2020, 6(10): 1571-1580. doi: 10.1001/jamaoncol.2020.3370
|
[12] |
Boku N, Ryu MH, Kato K, et al. Safety and efficacy of nivolumab in combination with S-1/capecitabine plus oxaliplatin in patients with previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: interim results of a randomized, phase Ⅱ trial (ATTRACTION-4)[J]. Ann Oncol, 2019, 30(2): 250-258. doi: 10.1093/annonc/mdy540
|
[13] |
Cohen R, Pudlarz T, Garcia-Larnicol ML, et al. Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase Ⅱ study is opened to recruitment[J]. Bull Cancer, 2020, 107(4): 438-446. doi: 10.1016/j.bulcan.2019.11.016
|
[14] |
Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲtrial[J]. J Clin Oncol, 2011, 29(13): 1715-1721. doi: 10.1200/JCO.2010.33.0597
|
[15] |
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. N Engl J Med, 2006, 355(1): 11-20. doi: 10.1056/NEJMoa055531
|
[16] |
Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial[J]. Lancet, 2019, 393(10184): 1948-1957. doi: 10.1016/S0140-6736(18)32557-1
|
[17] |
Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase Ⅲ trial[J]. J Clin Oncol, 2011, 29(13): 1715-1721. doi: 10.1200/JCO.2010.33.0597
|
[18] |
Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer[J]. New Engl J Med, 2006, 355(1): 11-20. doi: 10.1056/NEJMoa055531
|
[19] |
Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial[J]. Lancet, 2019, 393(10184): 1948-1957. doi: 10.1016/S0140-6736(18)32557-1
|
[20] |
Li X, Huang Q, Lei Y, et al. Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review[J]. Ann Transl Med, 2021, 9(6): 513. doi: 10.21037/atm-21-434
|
[21] |
Yu Y, Ma X, Zhang Y, et al. Changes in Expression of Multiple Checkpoint Molecules and Infiltration of Tumor Immune Cells after Neoadjuvant Chemotherapy in Gastric Cancer[J]. J Cancer, 2019, 10(12): 2754-2763. doi: 10.7150/jca.31755
|
[22] |
Smyth E, Knödler M, Giraut A, et al. VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study[J]. Front Oncol, 2019, 9: 1320.
|
[23] |
Petrillo A, Pompella L, Tirino G, et al. Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions[J]. Cancers (Basel), 2019, 11(3): 399. doi: 10.3390/cancers11030399
|
[24] |
Tian Y, Wang J, Qiao X, et al. Long-Term Efficacy of Neoadjuvant Concurrent Chemoradiotherapy for Potentially Resectable Advanced Siewert TypeⅡ and ⅢAdenocarcinomas of the Esophagogastric Junction[J]. Front Oncol, 2021, 11: 756440. doi: 10.3389/fonc.2021.756440
|
[25] |
Mole RH. Whole body irradiation; radiobiology or medicine?[J]. Br J Radiol, 1953, 26(305): 234-241. doi: 10.1259/0007-1285-26-305-234
|
[26] |
Sato H, Okonogi N, Nakano T. Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment[J]. Int J Clin Oncol, 2020, 25(5): 801-809.
|
[27] |
Merhi M, Raza A, Inchakalody VP, et al. Persistent anti-NY-ESO-1-specific T cells and expression of differential biomarkers in a patient with metastatic gastric cancer benefiting from combined radioimmunotherapy treatment: a case report[J]. J Immunother Cancer, 2020, 8(2): e001278. doi: 10.1136/jitc-2020-001278
|
[28] |
Wei J, Lu X, Liu Q, et al. Case Report: Neoadjuvant PD-1 Blockade Plus Concurrent Chemoradiotherapy in Unresectable Locally Advanced Gastric Cancer Patients[J]. Front Oncol, 2020, 10: 554040.
|
[29] |
Chung HC, Bang YJ, S Fuchs C, et al. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811[J]. Future Oncol, 2021, 17(5): 491-501. doi: 10.2217/fon-2020-0737
|
[30] |
Herbst RS, Arkenau HT, Santana-Davila R, et al. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial[J]. Lancet Oncol, 2019, 20(8): 1109-1123.
|
[31] |
Janjigian YY, Maron SB, Chatila WK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(6): 821-831. doi: 10.1016/S1470-2045(20)30169-8
|
[32] |
Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer[J]. J Clin Oncol, 2018, 36(28): 2836-2844.
|
[33] |
Bang YJ, Van Cutsem E, Fuchs CS, et al. KEYNOTE-585: Phase Ⅲ study of perioperative chemotherapy with or without pembrolizumab for gastric cancer[J]. Future Oncol, 2019, 15(9): 943-952.
|
Tables(1)